Teleflex Announces 200,000 Patients Treated with UroLift System for Enlarged Prostate
July 30 2020 - 6:00AM
Teleflex Incorporated (NYSE: TFX) today announced that 200,000
patients have been treated with the minimally invasive UroLift®
System for benign prostatic hyperplasia (BPH) worldwide.
Affecting more than 40 million men in the United States alone,1
BPH is a non-cancerous enlargement of the prostate that occurs as
men age and causes uncomfortable symptoms such as frequent
urination, weak urinary stream and the urgent need to urinate,
among others. The UroLift System provides rapid symptom relief and
a quick recovery time for patients. Men have the ability to return
to their normal routines and preserve sexual function with minimal
downtime.
“The UroLift System provides rapid and durable relief from
disruptive BPH symptoms, with minimal downtime,2,3” said Gregg
Eure, MD †, urologist at Urology of Virginia.
“Drugs for treatment of BPH can lead to sexual dysfunction,
headaches and dizziness, and have other negative side effects which
can ultimately prompt patients to stop using them.4 The UroLift
System has improved my patients’ quality of life and freed them
from the frequent interruptions caused by the burdensome symptoms
associated with BPH.”
“This milestone of 200,000 patients treated with the UroLift
System brings us closer to fulfillment of our mission: to improve
the lives of men suffering from the symptoms of BPH,” said Dave
Amerson, president of the Teleflex Interventional Urology business
unit. “We are gratified that physicians continue to recommend this
standard of care treatment to their patients and even choose it for
themselves, allowing them to potentially get off medication and
avoid major surgery. We are encouraged by the increasing amount of
positive real-world data on the UroLift System and the increased
adoption of this treatment among physicians.”
About the UroLift® SystemThe UroLift System is
a minimally invasive treatment for lower urinary tract symptoms due
to benign prostatic hyperplasia (BPH). It is indicated for the
treatment of symptoms of an enlarged prostate up to 100cc in men 45
years or older. As with any medical procedure, individual results
may vary. The UroLift permanent implants, delivered during an
outpatient procedure, relieve prostate obstruction without cutting,
heating, or removing prostate tissue. The UroLift System is the
only leading BPH procedure shown to not cause new onset, sustained
erectile or ejaculatory dysfunction in the L.I.F.T pivotal
study.2,4,5 Most common adverse events are temporary and can
include hematuria, dysuria, micturition urgency, pelvic pain, and
urge incontinence.1 Rare side effects, including bleeding and
infection, may lead to a serious outcome and may require
intervention. Consult the Instructions for Use (IFU) for more
information.The Prostatic Urethral Lift procedure (using the
UroLift System) is recommended for the treatment of BPH in both the
American Urological Association and European Association of Urology
clinical guidelines. More than 200,000 men have been treated with
the UroLift System in select markets worldwide.* As with any
medical procedure, individual results may vary. Learn more at
www.UroLift.com.
About Teleflex Interventional UrologyThe
Teleflex Interventional Urology Business Unit is dedicated to
developing innovative, minimally invasive and clinically effective
devices that address unmet needs in the field of urology. Our focus
is on improving the standard of care for patients with BPH using
the UroLift System, a minimally invasive permanent implant system
that treats symptoms while preserving sexual function. **2,4,5
Learn more at www.NeoTract.com.
About Teleflex IncorporatedTeleflex is a global
provider of medical technologies designed to improve the health and
quality of people’s lives. We apply purpose driven innovation – a
relentless pursuit of identifying unmet clinical needs – to benefit
patients and healthcare providers. Our portfolio is diverse, with
solutions in the fields of vascular and interventional access,
surgical, anesthesia, cardiac care, urology, emergency medicine and
respiratory care. Teleflex employees worldwide are united in the
understanding that what we do every day makes a difference. For
more information, please visit www.Teleflex.com.
Teleflex is the home of Arrow®, Deknatel®, Hudson RCI®, LMA®,
Pilling®, Rusch®, UroLift® and Weck® – trusted brands united by a
common sense of purpose.
Contacts:For Teleflex Incorporated:Jake
Elguicze, 610.948.2836Treasurer and Vice President, Investor
Relations
Media:Nicole Osmer, 650.454.0504nicole@healthandcommerce.com
|
|
1. |
NeoTract US Market Model estimates for 2018 based on IQVIA Health
Drug and Procedure data |
2. |
Roehrborn, J Urology 2013 LIFT Study |
3. |
Roehrborn, Can J Urol 2017 5 Year LIFT Study |
4. |
AUA BPH Guidelines 2003, 2010, 2018 amended 2019 |
5. |
McVary, J Sex Med 2016 |
|
|
|
† Dr. Gregg Eure is a paid consultant of
NeoTract/Teleflex*Management estimate based on product sales and
average units per procedure**No instances of new, sustained
erectile or ejaculatory dysfunction in the L.I.F.T pivotal
study |
|
|
|
Indicated for the treatment of symptoms of an enlarged prostate up
to 100cc in men 45 years or older. As with any medical procedure,
individual results may vary. Most common side effects are temporary
and include pain or burning with urination, blood in the urine,
pelvic pain, urgent need to urinate and/or the inability to control
the urge.2 Rare side effects, including bleeding and infection, may
lead to a serious outcome and may require intervention. Speak with
your doctor to determine if you may be a candidate. |
Teleflex (NYSE:TFX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Teleflex (NYSE:TFX)
Historical Stock Chart
From Apr 2023 to Apr 2024